October has been a tough month for biotech investorsPolitical turmoil and increasing chances that the Democrats might take the House of Representatives have been most unkind to the sectorAfter a rally in July that exceeded 15%, the main biotech indices spent August and September in a relatively tight trading range for this high-beta sectorHowever,...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.